Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Geron Corporation

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Apellis Pharmaceuticals, Inc. and Geron Corporation, two prominent players, have shown contrasting strategies over the past decade. From 2014 to 2023, Apellis saw a staggering increase in SG&A expenses, growing by over 17,000%, from approximately $2.9 million to $500 million. In contrast, Geron Corporation maintained a more stable trajectory, with expenses rising by about 312%, from $16.8 million to $69.1 million. This stark difference highlights Apellis's aggressive expansion strategy, while Geron appears to focus on steady, controlled growth. As investors and industry watchers analyze these trends, the question remains: which approach will yield better long-term results? The data suggests that while Apellis is investing heavily in growth, Geron's conservative approach may offer more sustainable financial management.